Federated Hermes Inc. Reduces Holdings in Omnicell, Inc. $OMCL

Federated Hermes Inc. reduced its position in Omnicell, Inc. (NASDAQ:OMCL) by 20.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 594,944 shares of the company’s stock after selling 151,555 shares during the period. Federated Hermes Inc. owned approximately 1.30% of Omnicell worth $17,491,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. GAMMA Investing LLC lifted its stake in shares of Omnicell by 37.1% in the second quarter. GAMMA Investing LLC now owns 1,694 shares of the company’s stock worth $50,000 after acquiring an additional 458 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Omnicell during the 2nd quarter valued at approximately $210,000. AlphaQuest LLC increased its holdings in Omnicell by 79.0% during the 1st quarter. AlphaQuest LLC now owns 6,400 shares of the company’s stock worth $224,000 after purchasing an additional 2,824 shares during the last quarter. EntryPoint Capital LLC raised its position in shares of Omnicell by 21.6% in the 1st quarter. EntryPoint Capital LLC now owns 6,671 shares of the company’s stock valued at $233,000 after purchasing an additional 1,184 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Omnicell by 7.4% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,040 shares of the company’s stock valued at $236,000 after purchasing an additional 552 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Stock Performance

OMCL stock opened at $43.97 on Thursday. The company has a current ratio of 1.44, a quick ratio of 1.21 and a debt-to-equity ratio of 0.14. The firm has a market cap of $1.97 billion, a P/E ratio of 102.26, a P/E/G ratio of 5.38 and a beta of 0.83. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $47.69. The stock’s 50 day simple moving average is $34.27 and its 200 day simple moving average is $31.76.

Insider Activity

In other news, EVP Corey J. Manley sold 3,880 shares of the firm’s stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $33.25, for a total value of $129,010.00. Following the transaction, the executive vice president directly owned 110,653 shares in the company, valued at approximately $3,679,212.25. This trade represents a 3.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 2.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on OMCL. Benchmark raised their price target on shares of Omnicell from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings reissued a “sell (d+)” rating on shares of Omnicell in a report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Omnicell currently has an average rating of “Hold” and an average target price of $43.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.